Gene Editing Therapy Shows Promise Against Severe Sickle Cell

Clinical trial results demonstrate potential of new gene-editing approach to treat debilitating blood disorder.

Apr. 10, 2026 at 5:23pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the sickle shape of a red blood cell, conceptually illustrating the genetic disorder targeted by a promising new gene-editing therapy.A new gene-editing therapy aims to correct the genetic mutation that causes the abnormal sickle shape of red blood cells, a hallmark of the debilitating sickle cell disease.Cleveland Today

New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease, a genetic blood disorder. The therapy, which uses CRISPR/Cas12a gene-editing technology, has the advantage of avoiding rejection, unlike traditional bone marrow transplants that are the current standard treatment.

Why it matters

Sickle cell disease is a debilitating inherited blood disorder that affects millions worldwide, causing severe pain, organ damage, and a shortened lifespan. Current treatments are limited, so a successful gene-editing therapy could dramatically improve outcomes for patients with this devastating condition.

The details

The gene-editing therapy works by using CRISPR/Cas12a technology to modify a patient's own blood stem cells, correcting the genetic mutation that causes sickle cell disease. This avoids the rejection issues seen with donor-based bone marrow transplants, which are the current standard of care.

  • The clinical trial results were announced on April 10, 2026.

The players

Rabi Hanna, M.D.

A physician at the Cleveland Clinic who is examining a patient undergoing the gene therapy treatment.

Cleveland Clinic

A renowned academic medical center in Ohio that is conducting the clinical trial of the gene-editing therapy for sickle cell disease.

Got photos? Submit your photos here. ›

What they’re saying

“We have seen that a benefit of this CRISPR/Cas12a gene-editing technology is that there is no rejection, so it's different from traditional bone marrow transplants, which is standard treatment for sickle cell patients currently.”

— Rabi Hanna, M.D., Physician, Cleveland Clinic

What’s next

The gene-editing therapy will now move forward to larger-scale clinical trials to further evaluate its safety and efficacy in treating severe sickle cell disease.

The takeaway

This promising gene-editing approach represents a potential breakthrough in the treatment of sickle cell disease, offering hope for patients suffering from this debilitating condition where current options are limited.